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Abstract: BACKGROUND In patients with diabetic foot osteomyelitis (DFO) who underwent surgical
debridement, we investigated whether a short (3 weeks), compared with a long (6 weeks) duration of
systemic antibiotic treatment is associated with non-inferior results for clinical remission and adverse
events (AE). METHODS In this prospective, randomized, non-inferiority, pilot trial, we randomized
(allocation 1:1), patients with DFO after surgical debridement to either a 3-week or a 6-week course of
antibiotic therapy. The minimal duration of follow-up after end of therapy was two months. We compared
outcomes using Cox regression and non-inferiority analyses (25% margin, power 80%). RESULTS Among
93 enrolled patients (18% females; median age 65 years), 44 were randomized to the 3-week arm and 49
to the 6-week arm. The median number of surgical debridement was 1 (range, 0-2 interventions). In the
intention-to-treat (ITT) population, remission occurred in 37 (84%) of the patients in the 3-week arm
compared to 36 (73%) in the 6-week arm (p=0.21). The number of AE was similar in the two study
arms (17/44 vs. 16/49; p=0.51), as were the remission incidences in the per-protocol (PP) population
(33/39 vs. 32/43; p=0.26). In multivariate analysis, treatment with the shorter antibiotic course was
not significantly associated with remission (for the ITT population, hazard ratio 1.1, 95%CI 0.6-1.7; for
the PP population hazard ratio 0.8, 95%CI 0.5-1.4). CONCLUSIONS In this randomized, controlled
pilot trial, a post-debridement systemic antibiotic therapy course for DFO of 3-weeks gave similar (and
statistically non-inferior) incidences of remission and AE to a course of 6 weeks.
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In this prospective-randomized pilot trial investigating the duration of post-
debridement antibiotic therapy for diabetic foot osteomyelitis, a short duration 
three weeks) was non-inferior to long duration (six weeks) for the outcomes of 


















































































































Background. In patients with diabetic foot osteomyelitis (DFO) who underwent 
surgical debridement, we investigated whether a short (3 weeks), compared with 
a long (6 weeks) duration of systemic antibiotic treatment is associated with non-
inferior results for clinical remission and adverse events (AE). 
Methods. In this prospective, randomized, non-inferiority, pilot trial, we 
randomized (allocation 1:1), patients with DFO after surgical debridement to 
either a 3-week or a 6-week course of antibiotic therapy. The minimal duration of 
follow-up after end of therapy was two months. We compared outcomes using 
Cox regression and non-inferiority analyses (25% margin, power 80%). 
Results. Among 93 enrolled patients (18% females; median age 65 years), 44 
were randomized to the 3-week arm and 49 to the 6-week arm. The median 
number of surgical debridement was 1 (range, 0-2 interventions). In the intention-
to-treat (ITT) population, remission occurred in 37 (84%) of the patients in the 3-
week arm compared to 36 (73%) in the 6-week arm (p=0.21). The number of AE 
was similar in the two study arms (17/44 vs. 16/49; p=0.51), as were the 
remission incidences in the per-protocol (PP) population (33/39 vs. 32/43; 
p=0.26). In multivariate analysis, treatment with the shorter antibiotic course was 
not significantly associated with remission (for the ITT population, hazard ratio 







































































































Conclusions. In this randomized, controlled pilot trial, a post-debridement 
systemic antibiotic therapy course for DFO of 3-weeks gave similar (and 
statistically non-inferior) incidences of remission and AE to a course of 6 weeks.  
Registration. Switzerland: BASEC 2016-01008; International: NCT03615807. 
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Diabetic foot osteomyelitis (DFO) is associated with high financial costs, 
frequent recurrences, and lower extremity amputations [1-5]. Because of the high 
potential for poor outcomes, many clinicians treat DFOs with a long course (>6 
weeks) of antibiotic therapy, despite the recommendation of guidelines to limit it 
to 4-6 weeks [1,3]. For example, a recent British analysis reported a duration of 
antibiotic therapy for DFO of less than six weeks in only 23% of cases, but of 3-6 
months in 34% and >6 months in 7% [6]. Similarly, a Canadian paper eported a 
median duration of oral antimicrobial therapy for DFO of 40 ± 30 weeks [7]. 
There are, in fact, few published data supporting a prolonged therapy for DFO, 
yet such an approach certainly increases the risk of side effects, development of 
antibiotic resistance, and costs [8,9].  
 
To help define proper antibiotic stewardship in DFO [2], we need randomized-
controlled trials (RCT) comparing the key outcomes with different durations of 
therapy. However, RCTs in the diabetic foot are difficult. Confounding issues 
include the presence and treatment of peripheral arterial disease, poor glycemic 
control, degree of bone destruction, and overall adherence [1,2,8-12]. A pilot 
study is often appropriate to provide information to help determine the feasibility 
and proper design of a larger confirmatory RCT. Based on our experience in 
patients with diabetic foot infections (DFI) performing RCTs [13,14], and 
investigating antibiotic optimization, we designed this pilot RCT comparing short 









































































































Setting and timeline 
We prospectively compared key outcomes of patients treated with a relatively 
short (3 weeks) versus a long (6 weeks) duration of antibiotic therapy for diabetic 
foot infection (DFI). The main (overall) trial had two stratifications: 1) soft tissue 
DFIs; and, 2) DFOs. For conciseness, we will publish the results for patients with 
soft tissue infections separately from this report. We began enrollment on 16 
February 2017, enrolled the last participant on 1st October 2019, and closed the 
database on 31 March 2020. The Geneva Ethical Committee approved the RCT 
(BASEC 2016-01008), which we registered internationally (ClinicalTrials.gov 
NCT03615807).  
 
Study Objectives and Criteria 
We assessed the clinical remission of DFO at two months after the designated 
End of Treatment (EOT). By unblinded randomization, we allocated all 
participants, in a ratio of 1:1, to either a short antibiotic therapy arm of (3 weeks ± 
2 days), or a long arm (6 weeks ± 2 days). The principal investigator (IU, or his 
replacements KG and TP) generated the allocation sequence in pre-fabricated 
sealed envelopes.  
Inclusion criteria were: age ≥18 years; diagnosis of diabetes mellitus (by 
American Diabetes Association criteria); having undergone appropriate 
debridement of all necrotic tissue; and, the presence of DFO.  
Exclusion criteria were: DFO associated with an implant; having received 
effective antibiotic therapy within the 96 previous hours; total clinical amputation 







































































































remote infection of any type requiring more than 21 days of another antibiotic 
therapy; e.g. concomitant endocarditis or prosthetic joint infection (Study 
protocol; Appendix 1).  
 
Treating clinicians were allowed to perform any needed wound debridement 
procedures, to choose the method of weight off-loading the affected foot, the 
appropriate diagnostic imaging methods [15], decide on the need for angioplasty, 
and to use negative-pressure vacuum therapy or hyperbaric oxygen for wound 
healing. While full resection of all infected bone was an exclusion, we permitted 
partial surgical amputation for necrotic bone. Our definition for “partial 
amputation” was purposely loose, including an amputation in one toe but leaving 
the DFO of another toe for conservative therapy, or a planned limited resection, 
such as during a partial calcanectomy [16,17]. If there was a partial amputation, 
we determined the presence of residual DFO by previous radiological and/or 
intraoperative assessments, and the decision to leave treat remaining DFO with 
antibiotic therapy. To limit the number of antibiotic drugs investigators might 
select, we provided a list of permitted agents from which the clinician could 
select the most appropriate (Appendix 2). Based on recent literature reporting on 
antibiotic therapy for DFO [8,16-20], clinicians were free to choose the 
administration route. For the microbiological diagnosis of DFO, we required 











































































































We defined DFO according to the criteria of the Infectious Diseases Society of 
America DFI guidelines [3], which include suggestive radiological, clinical 
and/or bone microbiological findings. We defined clinical remission of DFO as the 
complete absence of clinical and radiologic findings of infection after a minimal 
follow-up of two months after EOT. We defined clinical failure as either recurrent, 
persistent or new infection at the original site [21], or secondary amputation for 
progressive infection, ischemia or necrosis. We defined microbiological failure as a 
microbiologically-confirmed recurrence or persistence at the same localisation with 
the same pathogen (or at least one of the same pathogens in case of polymicrobial 
infection). We accepted off-loading as correct if it avoided of all mechanical stress 
on the infected site during most of the daytime. To assess the wound size (if there 
was any infected ulcer), we used a custom-made composite score from a prior RCT 
by our group [13]. This scale (4-30 points) measures wound depth, and visually 
assesses for undermining of the edges and redness; the score is the sum of the 
individual points (Appendix 3). An adverse event (AE) was any medical 
occurrence in a study participant during the trial.  
 
Study Conduct  
The full details are available in the Protocol (Appendix 1). The treatment period 
included the following (inpatient or outpatient) visits: visit 1 – Enrollment (Day 
1); visit 2 – Day 8 (± 4 days); visit 3 – Day 20 (± 4 days); visit 4 – Day 40 (± 4 
days) (only if still receiving treatment after Visit 3). The Test-of-Cure (TOC) visit 









































































































The primary outcome was clinical remission after a minimum follow-up of two 
months after EOT. The secondary outcome was the incidence of AEs in each 
study arm. For both outcomes, our pre-study estimate was an incidence of 80%, 
based on prior publications [2,3] and data from our medical centre's Clinical 
Pathway for DFO [9]. Using a binomial categorical, non-inferiority design, with 
an alpha level of 5%, a power of 80%, we needed 2 x 64 (128) episodes to 
achieve a non-inferiority margin of 25%. Expecting a dropout of 15%, we aimed 
to enrol at least 150 episodes for the overall study protocol, including soft tissue 
infections and DFO together. For DFOs alone, the sample size was at maximum 
100 episodes (Protocol summary; Appendix 1). For the formal non-inferiority 
proofs, we used the t-test with a (unidirectional) confidence interval of 90%. To 
adjust for the expected substantial case-mix, we planned a multivariate cluster-
controlled Cox regression analysis with the outcome “clinical remission” 
(clustering on the individual patients’ level). The intention-to-treat (ITT) 
population consisted of all randomized episodes. The per-protocol (PP) 
population included all participants who completed the study and whose 
treatment did not substantially deviate from the study protocol. We used 
STATA™ software (15.0; College Station, USA). 
Results 
Study population 
Our Clinical Pathway identified 346 DFIs and excluded 187 (54%) for the 
reasons shown in Figure 1. Excluding the 66 DFI patients who had solely diabetic 
foot soft tissue infection left 93 DFO episodes for the core analysis (ITT 







































































































median subject age was 65 years; the median American Society of 
Anesthesiologists-Score was 3 points; the median transcutaneous oxygen tension 
was 38 mmHg (dorsal foot); the median ankle-brachial index was 1; the median 
serum C-reactive protein level was 76 mg/L; and, the median body mass index 
was 27 kg/m2.  
 
Overall, there were 63 different microbiological constellations, including 
Staphylococcus aureus (the most common pathogen, identified in 44 [47%]), 
streptococci (10, 11%), gram-negative pathogens (28; 30%) and polymicrobial 
infections (48; 52%). These results were based on a median of 2 bone samples 
(interquartile range (IQR), 1-3 samples) per patient, although in 40 DFO cases the 
patient had received empirical systemic antibiotic therapy before bone sampling 
(prior median antibiotic duration 0 day, IQR, 0-3 d). The infection sites were the 
toes (n=53), the midfoot (31), and the hindfoot (11) and both the toes and the 
metatarsal regions (n=2). The comparison of demographic data for the two study 
arms showed they were well balanced (Table 2). 
 
Treatment  
Among the 93 included DFO episodes, 44 randomized to the 3-week arm and 49 
to the 6-week arm. Eight (9%) additionally underwent angioplasty and eleven 
(12%) had hyperbaric oxygen therapy for wound dehiscence. The median number 
of surgical debridement per episode was 1 (IQR, 0-2 interventions), among which 
34 (36%) were partial amputations. We used 47 different antibiotic regimens, 
which the most frequent agents being co-amoxiclav (63%), levofloxacin (22%), 







































































































administered in only 1 case. The median duration of the initial parenteral therapy 
was 2 days (IQR, 0-3 d). 
 
Outcomes 
Among the DFO episodes, 73 (78%) remained in total clinical remission after an 
active median follow-up of 11 months (IQR, 5-19 mts). The median passive 
follow-up (only telephone information or notes in medical files) was 17 months. 
Among the 20 clinical failures, eight were microbiological recurrences (8/93; 
9%): three in the 3-week and five in the 6-week treatment group. These 
recurrences mostly occurred 15 to 30 days after EOT. The other 12 failures 
yielded a new pathogen [21]. There was no difference in the incidence of clinical 
remission between the two study arms (Tables 1 and 2). Remission occurred in 37 
of 44 (84%) episodes in the 3-week arm compared to 36 of 49 (73%) in the 6-
week arm (p=0.21). The median Wound Score overall decreased from 17 to 4 
points, corresponding to a median decrease of 70%. Of note, at the time of 
database closure at the end of the passive follow-up, new clinical failures 
occurred in twenty episodes (1 acute Charcot foot and 19 new DFIs), and 26 




We noted 24 AE in 33 separate episodes (33/93; 35%), of which 14 were serious 
(SAE). The number of AE was similar in the two study arms (Table 2). While the 
most serious AE were unrelated to infection (7 acute ischemia, 3 postoperative 







































































































fungal intertrigo; 1 anaphylaxis to co-amoxiclav; 1 drug fever with 
cotrimoxazole; 3 skin rash to amoxicillin or levofloxacin; 1 severe diarrhea due to 
levofloxacin; and, 1 persistent nausea with clindamycin). No patient left the study 
because of an AE. One patient developed a symptomatic urinary tract infection 




Among the 93 DFO episodes composing the ITT population, we removed eleven 
(12%) when constituting the PP population (Figure 1). In the PP population, we 
treated 39 DFO episodes with a 3-week course of antibiotics and 43 during with a 
6-week course. In both study arms, the median number of surgical debridement 
was one. The incidence of clinical remission was similar to the ITT populations: 
33 of 39 episodes in the 3-week arm versus 32 of 43 episodes in the 6-week arm 
(85% vs 74%; p=0.26). The proportion of AE was also similarly distributed: 
15/39 in the 3-week versus 13/43 in the 6-week antibiotic arm (p=0.64). AE 
related to the study antibiotic therapy occurred in 4 in the 3-week versus 5 in the 
6-week arm (10% versus 12%, p=0.45). 
 
Multivariate adjustment 
Since the antibiotic therapy is only one part of the multipronged treatment 
program for DFO, we added a cluster-controlled Cox regression analysis further 
adjusting for non-randomized variables (Table 3). The treatment with the 3-week 







































































































remission (ITT population: HR 1.1, 95%CI 0.6-1.7). The corresponding 
multivariate result in the PP population was HR 0.8, 95%CI 0.5-1.4. 
 
Non-inferiority 
The statistical analysis of the results demonstrates non-inferiority of the shorter to 
the longer treatment duration. For remission, the confidence intervals excluded 
the 25%-margin (8.5 difference points [90%CI -24% to +4%] (ITT population). 
Similarly, there was a statistical non-inferiority for AE (10.0 difference points 
[90%CI -23% to +10%] (ITT population). The corresponding results in the PP 
population were 9.0 difference points [90%CI -25% to +5%] (remission) and 6.9 
difference points [90%CI -13% to +15%] (adverse events), respectively. 
 
Discussion 
The results of our single-center, real-life, pilot study in adult patients with DFO 
found that a relatively short course (3 weeks) of post-debridement antibiotic 
therapy was non-inferior to the standard duration of 6 weeks, albeit with a wide 
statistical margin of 25%. The incidence of clinical remission was 78%, which is 
similar to other studies in the literature [1-5].  
 
Standard practice in orthopedic surgery has been to treat most types of implant-
free osteoarticular infections, after undergoing adequate surgical debridement, 
with 4-6 weeks of antibiotic therapy [22-24]. Specifically, for DFO, a small 
French RCT compared a with antibiotic therapy (without surgery) for 6-weeks 
versus for 12-weeks and found a similar incidence of clinical remission. Based on 







































































































question of whether an even shorter duration of antibiotic therapy would be 
sufficient does not appear to have been evaluated [4]. In this RCT, AE occurred 
in up to 30% of the episodes, but there was no difference between the two 
antibiotic treatment duration arms. This finding is in line with previous 
publications, including our own [15,24-26].  
 
Our RCT has many strengths, but also has five important limitations. 
First, being a pilot study, further stratifications into more distinct populations, 
such as by the presence of limb ischemia, would require much larger sample 
sizes. Such RCTs would be difficult to perform, and unlikely to be funded 
without a prior pilot study.  
 
Second, while our estimated remission incidence of 80% matched well with the 
observed rate of 78%, our non-inferiority margin of 25% may appear to be too 
high. We justify this large margin by the non-lethal nature of most DFOs, the fact 
that this was a pilot study, and that antibiotic agents are only one part (arguably 
secondary to surgical resection) in the multifaceted treatment of DFO.  
 
Third, our minimal study follow-up period after treatment of two months might 
seem too short compared to the usual one to two years for implant-related 
infections. Recurrence of implant-free osteomyelitis can occur during many years 
after stopping of antibiotics [27]. However, we believe our relatively short 
follow-up is acceptable for several reasons: i) a short follow-up actually favors 
the long-treatment arm; ii) with a longer follow-up distinguishing between a 







































































































recurrences occurred between 15 and 30 days after EOT; and iv), it was designed 
as a "pilot-study," informing the decision to conduct more comprehensive RCTs 
in the field. 
 
Fourth, our real-life RCT included DFO episodes in which the subject underwent 
a partial amputation, which mechanically removes a substantial part of infection, 
leaving less infected bone for the antibiotics to treat. The proportion of partial 
amputations was a third (36%) in each arm. In our analyses, we could not detect a 
protective effect of the variable “partial amputation”. Recent studies suggest that 
(at least for forefoot DFO) the incidence of clinical remission is similar for 
patients treated predominantly by antibiotic therapy compared to surgery [1,5,8]. 
In our study, when excluding all partial amputations (24/27 vs. 20/27; p=0.16), or 
when excluding all surgical debridement (9/12 vs. 13/15; p=0.44), the 3-week 
course showed the same outcome as the 6-week course.  
We determined if there was persisting bone infection (in case of partial 
amputation) by pre-surgical radiological and/or intraoperative assessments. This 
situation differs from that in recent publications, demonstrating that DFO cases 
with microbiologically-positive margins of bone culture more often fail than 
cases without proof of missed residual infection [28]. Our setting is the exact 
opposite, as we left infected bone in situ on purpose. There are very few data 
concerning outcomes in this "inverse problem". Based on our own experience in 
Geneva, it is far more common to wrongly assume a clear amputation [28] than to 
remove all infected tissue during surgery that was not intentionally planned to do 







































































































Fifth, with 63 different microbiological constellations used among the 93 
episodes, we cannot compute the role of each individual pathogen on the 
likelihood of remission. As a general rule for orthopedic infections, including 
DFOs, the duration of the systemic antibiotic therapy does not depend on the 
species of isolated bacteria (except for mycobacteria or special pathogens such as 
actinomycetes or Nocardia) [1-5,8]. Indeed, the great majority of retrospective 
studies have failed to reveal a decisive, independent role of the isolated 
pathogens, even for methicillin-resistant Staphylococcus aureus [30]. In this pilot 
trial, we were only able to assess the role of the most common pathogen: S. 
aureus, and found that it played no decisive role in the analyses. 
 
Conclusion 
Our pilot trial suggests that a shorter duration of antibiotic therapy than currently 
recommended may be sufficient for treating DFO. These results suggest that there 
is a need for a larger RCT to see if it confirms our data. We have therefore started 
the confirmatory RCT with 400 planned episodes in Zurich [9], by using a non-
inferiority margin of 10%, a streamlined surgical approach with routine 
intraoperative biopsies of the residual bone stump, an initial radiological 
examination by magnetic resonance imaging [14], an evaluation of the nutritional 
scores and of the glycated hemoglobin levels, and a stratification between 
surgical versus totally antibiotic treatment approaches. We have also added a new 
side study investigating the duration of antibiotic therapy needed after total (not 
partial) amputations [29]. If we confirm our pilot findings, the clinical 
implications, especially for improved antibiotic stewardship of in the field of 
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Table 1. Characteristics and outcomes of subjects with a diabetic foot osteomyelitis episode by duration of treatment with systemic antibiotic therapy after 
debridement (intention-to-treat population) 
 
 








n = 93 n = 44 n = 49 value * 
Clinical    
Female sex 6 (14%) 11 (22%) .27 
Median age 70 years 65 years .23 





Osteomyelitis involving toe 22 (50%) 31 (63%) .20 







































































































Clinical peripheral arterial disease
 
27 (61%) 26 (53%) .42 
Transcutaneous O2 tension (dorsal foot; median) 36 mmHg 41 mmHg .58 
- Successful angioplasty performed 4 (9%) 4 (8%) .87 
Wound Score at admission (median) 16 points 17 points .56 
Pathogens    
Staphylococcus aureus  21 (48%) 23 (47%) .94 
Gram-negative bacteria 11 (25%) 17 (35%) .31 
Polymicrobial infection  20 (45%) 28 (57%) .26 
Therapy    
Number of surgical debridement (median) 1 intervention 1 intervention .27 







































































































Hyperbaric O2 therapy 6 (14%) 5 (10%) .61 
Duration of intravenous therapy (median) 1 day 3 days .37 
Outcomes    
Complete remission 37 (84%) 36 (73%) .21 
- Microbiological recurrences only 3 (7%) 5 (10%) .56 
Adverse events 17 (39%) 16 (33%) .54 
- Serious adverse events 5 (11%) 9 (18%) .35 
- Antibiotic-related adverse events 4 (9%) 7 (14%) .44 
Complete wound healing after therapy 28 (64%) 29 (59%) .67 









































































































Table 2. Characteristics of cases in which there was a clinical remission versus a clinical failure (intention-to-treat population) 
Diabetic foot osteomyelitis  Clinical Failure Clinical Remission p-  
n = 93 n = 20 n = 73 value *  
Female sex  2 (10%) 15 (21%) .28  
Median age 62 years 68 years .02  
Osteomyelitis involving toe (vs another anatomic site)
 
12 (60%) 41 (56%) .76  
Lower extremity angioplasty performed 0 (0%) 8 (11%) .12  
Osteomyelitis due to Staphylococcus aureus 12 (60%) 32 (44%) .10  
Number of surgical debridements (median) 1 intervention 1 intervention .83  







































































































Three-week course of antibiotic therapy 7 (35%) 37 (51%) .21  
Estimated % with adequate adherence by nurses/clinicians 18 (90%) 59 (81%) .34  
Length of hospital stay (median) 13 days 10 days .87  







































































































Table 3. Univariate and multivariate associations with the outcome “clinical remission” in the intention to treat (ITT) and per protocol (PP) populations 
  (Cox regression analysis; results expressed as hazard ratios with 95% confidence intervals) 
 
ITT Population Univariate Multivariate PP Population Univariate Multivariate  
n = 93 
  
n = 82    
Demographics       
Female sex 0.9, 0.5-1.6 - Female sex 1.0, 0.5-1.9 -  
Age 1.0, 1.0-1.0 - Age 1.0, 1.0-1.0 -  
Body mass index 1.0, 0.9-1.0 - Body Mass Index 1.0, 0.9-1.0 -  
Toe osteomyelitis 1.0, 0.6-1.7 - Toe osteomyelitis 1.2, 0.7-2.1 -  
Peripheral arterial disease
 
0.9, 0.5-1.5 - Peripheral arterial disease
 
0.9, 0.5-1.6 -  
Ankle-brachial index 0.7, 0.2-1.9 - Ankle-Brachial Index 0.8, 0.3-2.2 -  
- Angioplasty 1.4, 0.6-3.2 1.6, 0.8-3.2 - Angioplasty 1.9, 0.8-4.6 1.9, 0.9-3.8  
Wound Score (size) at admission 1.0, 1.0-1.0 - 
Wound Score (size) at 
admission 
1.0, 0.9-1.0 -  
Pathogen   Pathogens    
Staphylococcus aureus  1.1, 0.7-1.9 1.4, 0.8-2.4 Staphylococcus aureus  1.1, 0.6-1.8 1.3, 0.8-2.1  







































































































Polymicrobial infection  1.4, 0.8-2.3 - Polymicrobial infection  1.3, 0.7-2.2 -  
Therapy   Therapy    
3-week antibiotic therapy arm  1.0, 0.6-1.6 1.1, 0.6-1.7 
Short (3-week) antibiotic 
therapy  
0.8, 0.4-1.3 0.8, 0.5-1.4  
Intravenous antibiotic duration 1.0, 1.0-1.0 1.0, 1.0-1.0 
Intravenous antibiotic 
duration 
1.0, 1.0-1.0 1.0, 1.0-1.0  
Number of surgical debridement 1.0, 0.8-1.2 - 
Number of surgical 
debridement 
1.1, 0.8-1.5 -  
- Partial amputations 0.7, 0.4-1.2 0.5, 0.2-0.9 - Partial amputations 0.6, 0.3-1.1 0.5, 0.3-1.0  
Adequate patient adherence 0.9, 0.5-1.7 - 
Adequate patient’s 
adherence 
0.6, 0.3-1.2 -  
 
* Statistically significant results are displayed in bold and italic.  “ - “ = not included in the multivariate model 
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